Targeting ferroptosis in neuroimmune and neurodegenerative disorders for the development of novel therapeutics - 16/06/24
Abstract |
Neuroimmune and neurodegenerative ailments impose a substantial societal burden. Neuroimmune disorders involve the intricate regulatory interactions between the immune system and the central nervous system. Prominent examples of neuroimmune disorders encompass multiple sclerosis and neuromyelitis optica. Neurodegenerative diseases result from neuronal degeneration or demyelination in the brain or spinal cord, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. The precise underlying pathogenesis of these conditions remains incompletely understood. Ferroptosis, a programmed form of cell death characterised by lipid peroxidation and iron overload, plays a pivotal role in neuroimmune and neurodegenerative diseases. In this review, we provide a detailed overview of ferroptosis, its mechanisms, pathways, and regulation during the progression of neuroimmune and neurodegenerative diseases. Furthermore, we summarise the impact of ferroptosis on neuroimmune-related cells (T cells, B cells, neutrophils, and macrophages) and neural cells (glial cells and neurons). Finally, we explore the potential therapeutic implications of ferroptosis inhibitors in diverse neuroimmune and neurodegenerative diseases.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Summarized the mechanisms and pathways of ferroptosis, and its susceptibility to environmental factors. |
• | Clarified the potential role of ferroptosis in neuroimmune and neurodegenerative diseases. |
• | Provided an overview of the localization of ferroptosis in immune and neural cells of CNS immune and degenerative diseases. |
• | Presented a summary of ferroptosis inhibitors for novel therapeutic development. |
Keywords : Ferroptosis, Signaling, Neuroimmune disorders, Neurodegenerative disorders, Inhibitor
Plan
Vol 176
Article 116777- juillet 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?